Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Axonics Inc (AXNX)
Axonics Inc (AXNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,878,615
  • Shares Outstanding, K 50,662
  • Annual Sales, $ 273,700 K
  • Annual Income, $ -59,700 K
  • 60-Month Beta 0.48
  • Price/Sales 10.71
  • Price/Cash Flow N/A
  • Price/Book 4.80
Trade AXNX with:

Options Overview Details

View History
  • Implied Volatility 42.15% ( -1.27%)
  • Historical Volatility 35.78%
  • IV Percentile 10%
  • IV Rank 38.61%
  • IV High 69.70% on 10/12/23
  • IV Low 24.82% on 06/14/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 38
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 1,756
  • Open Int (30-Day) 1,894

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 0.05
  • Number of Estimates 7
  • High Estimate 0.10
  • Low Estimate -0.02
  • Prior Year 0.01
  • Growth Rate Est. (year over year) +400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.70 +14.33%
on 11/10/23
60.34 -5.83%
on 11/15/23
+3.88 (+7.33%)
since 11/08/23
3-Month
48.30 +17.64%
on 10/30/23
61.84 -8.12%
on 09/12/23
-1.31 (-2.25%)
since 09/08/23
52-Week
47.59 +19.39%
on 05/31/23
68.93 -17.57%
on 12/13/22
-9.07 (-13.77%)
since 12/08/22

Most Recent Stories

More News
Axonics: Q3 Earnings Snapshot

Axonics: Q3 Earnings Snapshot

AXNX : 56.82 (-1.83%)
Why Shares of Axonics Rose Friday

The company showed improved revenue and margins in its second-quarter report.

MDT : 79.35 (-0.25%)
AXNX : 56.82 (-1.83%)
Axonics: Q2 Earnings Snapshot

Axonics: Q2 Earnings Snapshot

AXNX : 56.82 (-1.83%)
Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates

Axonics (AXNX) delivered earnings and revenue surprises of 44.12% and 9.85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AXNX : 56.82 (-1.83%)
HCAT : 7.76 (+0.78%)
Axonics: Q1 Earnings Snapshot

Axonics: Q1 Earnings Snapshot

AXNX : 56.82 (-1.83%)
Axonics Reports First Quarter 2023 Financial Results

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results...

AXNX : 56.82 (-1.83%)
Axonics to Participate in Upcoming Investor Conferences

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in...

AXNX : 56.82 (-1.83%)
Axonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the acquisition...

AXNX : 56.82 (-1.83%)
Axonics to Report First Quarter 2023 Financial Results on May 1

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report first...

AXNX : 56.82 (-1.83%)
Axonics Ranked No. 2 on the Financial Times 2023 List of the Fastest Growing Companies in the Americas

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No....

AXNX : 56.82 (-1.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Axonics Modulation Technologies Inc. is focused on development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction and disrupting the SNM market. Axonics Modulation Technologies Inc. is based in Irvine, CA.

See More

Key Turning Points

3rd Resistance Point 59.62
2nd Resistance Point 58.96
1st Resistance Point 57.89
Last Price 56.82
1st Support Level 56.16
2nd Support Level 55.50
3rd Support Level 54.43

See More

52-Week High 68.93
Fibonacci 61.8% 60.78
Fibonacci 50% 58.26
Last Price 56.82
Fibonacci 38.2% 55.74
52-Week Low 47.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar